Clinical Response News Today

Before deciding to proceed with weight loss surgery or Bariatric Surgery, here are a few things that patients should discuss with their doctor | Health

Results Reveal Mechanism of Action and Correlative Analyses DataHELSINKI, Finland, April 10, 2024 (GLOBE NEWSWIRE) -- TILT Biotherapeutics (TILT), a clinical-stage biotechnology company developing cancer immunotherapies presented promising preliminary safety and efficacy data from their ongoing Phase I clinical trial (NCT05271318) in platinum resistant or refractory ovarian cancer patients at the American Association for Cancer Research (AACR) Annual Meeting 2024. TILT-123 in combination with MS

/PRNewswire/ -- Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application...

1. In this randomized controlled trial, depressed patients who received Meditation-Based Lifestyle Modification (MBLM) had a greater increase in spirituality than those who received treatment as usual. 2. Furthermore, baseline interest in spirituality and engagement in mind-body practice were two predictive factors of improved depression and perceived stress in response to treatment. Evidence Rating Level:

- SLS009 Demonstrated Promising Efficacy in Phase 1 Study with 36.4% Clinical Response in r/r Peripheral T-cell Lymphomas ; ORR in r/r PTCL Patients with Standard of Care is 25.8% - - One Patient...

First presentation of results from primary analysis of Phase 2 TRANSCEND FL study evaluating second-line treatment with Breyanzi® in relapsed or refractory follicular lymphoma demonstrate its...

- SLS009 Demonstrated Promising Efficacy in Phase 1 Study with 36.4% Clinical Response (ORR) in r/r Peripheral T-cell Lymphomas (PTCL); ORR in r/r PTCL...

Results presented in a paper at ACG 2023 showed upadacitinib was more effective than ustekinumab for achieving clinical response and endoscopic remission.

Announced by AbbVie on October 15, 2023, positive results revealed 59% of patients treated with risankizumab and 40% of patients treated with ustekinumab achieved clinical remission, respectively.

Phase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis SuppurativaBimekizumab treatment resulted in clinically meaningful improvements in HiSCR50 and the more stringent endpoints HiSCR75, HiSCR90 and HiSCR100 vs. placebo at Week 16, with improvem...